Immunovant upped on positive trial, Docusign raised to Hold: 5 big analyst picks

By Davit Kirakosyan

Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Immunovant, Edwards Lifesciences, International Paper, Docusign, and Teradyne.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Immunovant earns an upgrade following positive IMVT-1402 results

Raymond James upgraded Immunovant (NASDAQ:IMVT) to Outperform from Market Perform with a price target of $40.00 following the release of both Single Ascending Dose (SAD) and preliminary Multiple Ascending Dose (MAD) data for its next-generation anti-FcRn therapeutic, IMVT-1402. As a result, shares jumped more than 97% yesterday.

"While it's premature to call '1402 'best-in-class,' there is room for more than one anti-FcRn agent in the market, and we believe multiple agents can achieve blockbuster status," mentioned Raymond James.

The firm considers the MAD data a significant risk-reducing development for Immunovant and, therefore, is upgrading the stock.

International Paper earns another upgrade

International Paper (NYSE:IP) shares gained more than 1% pre-market today after Jefferies upgraded the company to Hold from Underperform and raised its price target to $33.00 from $26.00, as reported in real-time on InvestingPro.

Last week, Truist Securities upgraded the company to Buy from Hold with a price target of $43.00 (from $30.00).

The company is set to report its Q3 earnings results next month.

InvestingPro | Know Market Moves

Edwards Lifesciences upgraded to Outperform at Oppenheimer

Oppenheimer upgraded Edwards Lifesciences (NYSE:EW) to Outperform from Perform with a price target of $90.00, citing an attractive risk-reward profile, dismissing concerns about GLP-1, and highlighting the substantial opportunity in Transcatheter Tricuspid Valve Replacement (TTVR).

While Oppenheimer is positive on the stock, there was some negative news for the company Tuesday morning after reports stated Edwards Lifesciences was raided by EU antitrust regulators at one of its facilities in the region a week ago. Citing two people with direct knowledge of the matter, Reuters said the move highlights increasing regulatory scrutiny of the pharmaceutical industry. The publication added that the European Commission said on September 19 that it raided a cardiovascular medical device company due to concerns it may have abused its market power in breach of the bloc's antitrust rules.

2 more upgrades

DocuSign (NASDAQ:DOCU) shares rose more than 1% pre-market today after HSBC upgraded the company to Hold from Reduce with a price target of $42.00.

Northland Capital Markets upgraded Teradyne (NASDAQ:TER) to Outperform from Market Perform with a price target of $126.00.

We see several factors that will drive semiconductor test intensity in the future. These include the transition to 3nm at TSMC, HBM DRAM, vertically integrated product companies, and systems in package.

In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.5% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network
  • London Office
    One Financial Markets 

    1 Finsbury Market
    EC2A 2BN
    United Kingdom

    T:  + 44 ( 0 ) 203 857 2000
  • Dubai Office
    One Financial Markets 
    OT19-39 Central Park Tower
    Dubai International Finance Centre
    United Arab Emirates
    T: + 971 44 22 888

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: